Cargando…
A-002 (Varespladib), a phospholipase A(2 )inhibitor, reduces atherosclerosis in guinea pigs
BACKGROUND: The association of elevated serum levels of secretory phospholipase A(2 )(sPLA(2)) in patients with cardiovascular disease and their presence in atherosclerotic lesions suggest the participation of sPLA(2 )enzymes in this disease. The presence of more advanced atherosclerotic lesions in...
Autores principales: | Leite, Jose O, Vaishnav, Ushma, Puglisi, Michael, Fraser, Heather, Trias, Joaquim, Fernandez, Maria Luz |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2653470/ https://www.ncbi.nlm.nih.gov/pubmed/19222850 http://dx.doi.org/10.1186/1471-2261-9-7 |
Ejemplares similares
-
Structural basis for phospholipase A(2)-like toxin inhibition by the synthetic compound Varespladib (LY315920)
por: Salvador, Guilherme H. M., et al.
Publicado: (2019) -
Ex Vivo Effect of Varespladib on Secretory Phospholipase A2 Alveolar Activity in Infants with ARDS
por: De Luca, Daniele, et al.
Publicado: (2012) -
Varespladib Inhibits the Phospholipase A(2) and Coagulopathic Activities of Venom Components from Hemotoxic Snakes
por: Xie, Chunfang, et al.
Publicado: (2020) -
Anticoagulant Activity of Naja nigricollis Venom Is Mediated by Phospholipase A2 Toxins and Inhibited by Varespladib
por: Kazandjian, Taline D., et al.
Publicado: (2021) -
The BRAVO Clinical Study Protocol: Oral Varespladib for Inhibition of Secretory Phospholipase A2 in the Treatment of Snakebite Envenoming
por: Carter, Rebecca W., et al.
Publicado: (2022)